ONO 4817
(Synonyms: MMP Inhibitor V) 目录号 : GC15005
An inhibitor of MMP-2 and MMP-9
Cas No.:223472-31-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
ONO 4817 is a potent inhibitor of MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-13 with IC50 value of 0.73 nM, 42 nM, 2500 nM, 1.1 nM, 2.1 nM, 0.45 nM and 1.1 nM, respectively [1].
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that belong to the metzincin superfamily and play an important role in tissue remodeling associated with various physiological or pathological processes such as morphogenesis, angiogenesis, tissue repair, cirrhosis, arthritis, and metastasis. It has been reported that MMPs involve in the tumor invasion and angiogenesis processes [1].
ONO 4817 is a potent MMP inhibitor and has a quite spread spectrum on MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-13, while has no effect on MMP-1 . When tested with the supernatant of lung cancer cell line PCI14PE6 cells, ONO 4817 caused the inhibition on the activities of MMP-2 and MMP-9 in a dose dependent manner (0.1-10 μM) [2].
In nude mice model with PC14 or PC14PE6 subcutaneous xenograft that produced metastasis only in the lungs, administration of ONO 4817 caused significant reduction of the number of lung metastasis, inhibited the formation of pleural effusion and decreased the tumor volumes [2]. In Sprague-Dawley rat model, ONO 4817 treatment (5 mg) significantly inhibited thickening of the submesothelial layer and accumulation of type I collagen in the peritoneum and prevented the increase of the number of macrophages and blood vessels [3].
References:
[1]. Okamoto, Y., et al., A matrix metalloproteinase inhibitor, ONO-4817, suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit. Int Heart J, 2007. 48(3): p. 369-78.
[2]. Shiraga, M., et al., Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res, 2002. 62(20): p. 5967-73.
[3]. Ro, Y., et al., Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant, 2007. 22(10): p. 2838-48.
| Cas No. | 223472-31-9 | SDF | |
| 别名 | MMP Inhibitor V | ||
| 化学名 | N-[1-(ethoxymethoxy)-5-(hydroxyamino)-4-methyl-5-oxopentan-2-yl]-4-phenoxybenzamide | ||
| Canonical SMILES | CCOCOCC(CC(C)C(=O)NO)NC(=O)C1=CC=C(C=C1)OC2=CC=CC=C2 | ||
| 分子式 | C22H28N2O6 | 分子量 | 416.47 |
| 溶解度 | <20.82mg/ml in ethanol; <41.65mg/ml in DMSO | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4011 mL | 12.0057 mL | 24.0113 mL |
| 5 mM | 0.4802 mL | 2.4011 mL | 4.8023 mL |
| 10 mM | 0.2401 mL | 1.2006 mL | 2.4011 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。